Results 21 to 30 of about 1,680 (126)

Influence of emicizumab on protein C-mediated clotting regulation

Bleeding, Thrombosis and Vascular Biology, 2023
Emicizumab, a FVIII-mimetic bispecific antibody, is insensitive to degradation by activated protein C (APC) and may thus induce a procoagulant state. We investigated the effect of emicizumab on protein C-mediated inhibition of coagulation under in vitro
Federica Mancazzo, Antonia Vitulli, Lavinia Dirienzo, Concetta T. Ammollo, Fabrizio Semeraro, Mario Colucci   +5 more
doaj   +1 more source

Emicizumab-induced photosensitivity

TH Open, 2022
AbstractEmicizumab constitutes a novel and effective prophylaxis for hemophilia A patients with and without inhibitors. In this case report, we describe an emicizumab-induced photosensitivity that forced permanent sun-exposure suppression. To the best of our knowledge, this side effect had not been communicated until present.
Pedro Asensi Cantó, Mercedes Rodríguez Serna, Pilar Lloret Madrid, Jürgen Solís Ruiz, Ana Rosa Cid Haro, Santiago Bonanad Boix, Saturnino Haya Guaita   +6 more
openaire   +3 more sources

Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study

Research and Practice in Thrombosis and Haemostasis, 2022
Background Emicizumab is a new treatment option for people with hemophilia A. Emicizumab was approved with a body‐weight‐based dosage regimen, without laboratory monitoring requirements.
Anouk A. M. T. Donners, László Gerencsér, Kim C. M. van derElst, Toine C. G. Egberts, Moniek P. M. deMaat, Albert Huisman, Rolf T. Urbanus, Mohsin El Amrani   +7 more
doaj   +1 more source

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report

Research and Practice in Thrombosis and Haemostasis, 2021
Background Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks and side effects compared to factor VIII products.
Beth Boulden Warren, Adrian Chan, Marilyn Manco‐Johnson, Brian R. Branchford, Tyler W. Buckner, Genevieve Moyer, Elizabeth Gibson, Dianne Thornhill, Michael Wang, Christopher J Ng   +9 more
doaj   +1 more source

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience

Hematology Reports, 2023
Prophylactic treatment with emicizumab has become an important and effective bleeding prevention for people with hemophilia A (PwHA). Perioperative management of PwHA using emicizumab prophylaxis is still challenging due to a lack of experience.
Karla Rener, Saša Anžej Doma, Martina Fink, Helena Podgornik, Irena Preložnik Zupan   +4 more
doaj   +1 more source

No correlation between thrombin generation and emicizumab levels: implications for monitoring emicizumab therapy

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab, a bispecific antibody that mimics factor (F)VIII, has significantly improved hemophilia A management. Although emicizumab levels can be measured, tools for estimating the hemostatic efficacy of emicizumab are lacking.
Konrad van der Zwet, Mark Roest, Dana Huskens, Roger E.G. Schutgens, Lize F.D. van Vulpen, Kathelijn Fischer, Rolf T. Urbanus   +6 more
doaj   +1 more source

Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

Scientific Reports, 2023
Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy of emicizumab have been demonstrated in several clinical trials.
Raquel Valls, Jonathan Wagg, Ido Paz-Priel, Gabriel Man, Laura Artigas, Georges Jaccard, Mireia Coma, Christophe Schmitt   +7 more
doaj   +1 more source

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro

TH Open, 2018
Emicizumab is a humanized bispecific antibody that binds simultaneously to factor (F) IXa and FX replacing the cofactor function of FVIIIa. Because emicizumab recognizes FIX/FIXa and FX/FXa, a question may arise whether emicizumab competes with ...
Mariko Noguchi-Sasaki, Tetsuhiro Soeda, Atsunori Ueyama, Atsushi Muto, Michinori Hirata, Hidetomo Kitamura, Kaori Fujimoto-Ouchi, Yoshiki Kawabe, Keiji Nogami, Midori Shima, Takehisa Kitazawa   +10 more
doaj   +1 more source

Evaluation of Safety and Efficacy of Emicizumab Prophylaxis in Egyptian Pediatric Patients with Hemophilia A

Turkish Journal of Hematology
Objective: Hemophilia A (HA) is a hereditary X-linked bleeding disorder secondary to deficiency of the clotting factor VIII (FVIII). Emicizumab is a monoclonal antibody that replaces the function of the activated FVIII and prevents bleeding in HA ...
Tamer Hassan, Marwa Zakaria, Manar Fathy, Ahmed Farag, Eman Abdelhady, Dalia Gameil, Mustafa Abu Hashem   +6 more
doaj   +1 more source

Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels.

PLoS ONE, 2022
Emicizumab mimics the hemostatic activity of activated factor VIII (FVIIIa) within the tenase complex. Despite functional similarities between FVIIIa and emicizumab, conventional laboratory methods designed for monitoring of FVIII activity are ...
Nasim Shahidi Hamedani, Johannes Oldenburg, Bernd Pötzsch, Jens Müller   +3 more
doaj   +1 more source